OncLive TV

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

James K. McCloskey II, MD, discusses the results of the phase III ASCERTAIN trial in myelodysplastic syndrome.

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Hope S. Rugo, MD, discusses results of a randomized phase III trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Mike Cusnir, MD, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Alexander Leandros Lazarides, MD, discusses some of the current challenges in moving the field forward in osteosarcoma.

Hossein Borghaei, DO, MS, discusses immune-related adverse events in patients with lung cancer who received immunotherapy/chemotherapy combinations.

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and the chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Ulka Vaishampayan, MD, discusses trials that examine frontline immunotherapy for metastatic kidney cancer.

Thomas G. Martin, MD, discusses the impact of subcutaneous administration of daratumumab on patients with early relapse multiple myeloma.

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.